This conversion of cancer cells towards a more mesenchymal phenotype involves loss or lowered expression of epithelial markers (e.g. E-Cad and keratins), increased expression of mesenchymal markers (e.g. N-Cad, vimentin, fibronectin), increased mobility and an invasive phenotype [3], [4], [5]. The gene discussed is CDH2; the disease is cancer.